Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: A pragmatic cluster randomized controlled trial study protocol by unknown
Clouston et al. BMC Cancer 2012, 12:182
http://www.biomedcentral.com/1471-2407/12/182STUDY PROTOCOL Open AccessDoes access to a colorectal cancer screening
website and/or a nurse-managed telephone help
line provided to patients by their family physician
increase fecal occult blood test uptake?: A
pragmatic cluster randomized controlled trial
study protocol
Kathleen Clouston1*, Alan Katz2, Patricia J Martens3, Jeff Sisler4, Donna Turner5, Michelle Lobchuk6 and
Susan McClement7CIHR/CCMB Team in Primary Care Oncology (PCO-NET)Abstract
Background: Fecal occult blood test screening in Canada is sub-optimal. Family physicians play a central role in
screening and are limited by the time constraints of clinical practice. Patients face multiple barriers that further
reduce completion rates. Tools that support family physicians in providing their patients with colorectal cancer
information and that support uptake may prove useful. The primary objective of the study is to evaluate the
efficacy of a patient decision aid (nurse-managed telephone support line and/or colorectal cancer screening
website) distributed by community-based family physicians, in improving colorectal cancer screening rates.
Secondary objectives include evaluation of (dis)incentives to patient FOBT uptake and internet use among 50 to 74
year old males and females for health-related questions. Challenges faced by family physicians in engaging in
collaborative partnerships with primary healthcare researchers will be documented.
Methods/design: A pragmatic, two-arm, randomized cluster controlled trial conducted in 22 community-based
family practice clinics (36 clusters) with 76 fee-for-service family physicians in Winnipeg, Manitoba, Canada. Each
physician will enroll 30 patients attending their periodic health examination and at average risk for colorectal
cancer. All physicians will follow their standard clinical practice for screening. Intervention group physicians will
provide a fridge magnet to each patient that contains information facilitating access to the study-specific colorectal
cancer screening decision aids (telephone help-line and website). The primary endpoint is patient fecal occult
blood test completion rate after four months (intention to treat model). Multi-level analysis will include clinic,
physician and patient level variables. Patient Personal Health Identification Numbers will be collected from those
providing consent to facilitate analysis of repeat screening behavior. Secondary outcome data will be obtained
through the Clinic Characterization Form, Patient Tracking Form, In-Clinic Patient Survey, Post-Study Follow-Up
Patient Survey, and Family Physician Survey. Study protocol approved by The University of Manitoba Health
Research Ethics Board.
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Discussion: The study intervention has the potential to increase patient fecal occult blood test uptake, decrease
colorectal cancer mortality and morbidity, and improve the health of Manitobans. If utilization of the website and/
or telephone support line result in clinically significant increases in colorectal cancer screening uptake, changes in
screening at the policy- and system-level may be warranted.
Trial registration: Clinical trials.gov identifier NCT01026753
Keywords: Colorectal cancer screening, Fecal occult blood test, Community-based Primary healthcare research,
Community-based clinical practice, Family physicians, Patient decision aid, Pragmatic, Cluster randomized controlled
trial, Integrated knowledge translation, Knowledge exchangeBackground
The CIHR/CancerCare Manitoba Team in Primary Care
Oncology Research is based in Winnipeg, Manitoba,
Canada and is one of five Canadian Institutes of Health
Research (CIHR) Primary Care Oncology New Emerging
Team (PCO-NET) grant recipients (Additional file 1).
The focus of our research is to investigate ways of sup-
porting community-based family physicians in providing
colorectal cancer services throughout the care con-
tinuum. We are a multi-disciplinary team of stakeholders
and knowledge users including primary healthcare
researchers, practitioners, policy and decision makers,
and patients. The purpose of this team is to develop re-
search initiatives that support evidence-based primary
care oncology clinical practice, thus providing access to
high quality cancer care.
Each week, approximately 430 Canadians will be diag-
nosed with colorectal cancer (CRC) and 175 will die of
the disease, making it the second leading cause of cancer
related death in Canada [1]. In Manitoba, CRC is the
third most commonly diagnosed cancer (with an esti-
mated 810 new cases in 2011) and the second leading
cause of death from cancer in men and women com-
bined (with an estimated 320 deaths in 2011) [1]. Colo-
rectal cancer (CRC) screening rates for average risk
individuals are sub-optimal in across Canada and in
Manitoba [2]. Self-reported data from Manitobans indi-
cates that approximately 38% of eligible individuals have
completed an FOBT in the past two years [3]. This fig-
ure is close to that reported by Statistics Canada (2009)
indicating FOBT screening rates for Manitobans of
41.9% [1]. Increased screening would reduce the phys-
ical, emotional and economic burden of CRC. It has
been estimated that if approximately 70% of Canadians
aged 50 to 74 completed an FOBT every two years, fol-
lowed up by colonoscopy for positive FOBTs, the CRC
mortality rate could be reduced by 17% [4-6].
Ninety three percent of all cases of CRC occur in those
over the age of 50 and the incidence rate of the disease is
expected to increase by 20% by 2025 [1,7]. CRC is a silent
disease with overt symptoms not usually occurring until
an advanced stage [8]. Early detection and treatment isvital in reducing the disease impact because survival
decreases with increasing stage of disease at diagnosis
[9]. Randomized control trials have shown that screening
using the FOBT can reduce mortality from CRC by 25%
[10]. A number of Canadian organizations have outlined
CRC screening recommendations emphasizing FOBT at
least every two years for average risk men and women
between 50 to 74 years of age [1,11-14].
In Manitoba, patients may access FOBT screening
through one of two routes: (1) a population-based
screening program (ColonCheck) in Manitoba promotes
screening through direct mailing, distribution at mam-
mography clinics, the Mobile Breast Screening Program,
publicity campaigns) but is not yet available to all Mani-
tobans, and (2) Family physicians (FPs) which are the
second access point to screening with an FOBT. The
complexities of clinical practice and time constraints of
the FP impact on the time available to adequately address
all health concerns during the periodic health examin-
ation, especially prevention and screening [15]. Today,
family physicians are responsible for caring for patients
with increasingly complex multiple morbidities [16,17]
and face challenges in addressing health promotion
within the time constraints of clinical practice. Practi-
tioners may also have insufficient time to access current
evidence-based research findings and guidelines to sup-
port them in their CRC screening efforts [18], making
knowledge translation activities between researchers and
practitioners a vital component of the protocol objectives
in the context of primary care research.
Tools that support family physicians in providing their
patients with CRC screening information and support
them in completing the test may prove useful in improv-
ing FOBT uptake among patients. In clinical practice,
patients are usually given the FOBT through a labora-
tory requisition at their periodic health examination
(PHE), provided the FOBT card from the physician’s
support staff, or given it directly by their family phys-
ician and instructed to return it to the laboratory after
they have completed it (unpublished observations; KC).
The first point of contact for a majority of patients
seeking healthcare is with a community-based family
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healthcare delivery, including CRC screening [19]. Mani-
tobans depend on their family physicians to inform them
of the need for FOBT testing in the prevention of CRC
[8]. Physicians estimate it takes approximately four min-
utes to do a good job of explaining CRC and relevant
screening options [20]. This represents between 27 and
40% of the total time available during the periodic health
examination. In 2005, a study by Stokamer et al. demon-
strated an increase in FOBT compliance from 51.3% to
65.9% using intensive one-on-one CRC education by
registered nurses that took an additional 4.6 minutes be-
yond the time of standard CRC screening patient educa-
tion (consisting of written instructions for the FOBT and
verbal instruction to return the completed test within
two weeks) [20]. Family physicians require supportive
tools to facilitate FOBT recommendation and compli-
ance among their patients to improve overall FOBT
screening rates. Research is required to identify innova-
tive methods of supporting family physicians in their
role in CRC screening. Developing strategies aimed at
supporting both the primary care provider as well as
their patients has the potential to lead to substantial
improvements in FOBT screening rates. Patient educa-
tion about CRC and the importance of screening has
been demonstrated to improve patient knowledge and
compliance with FOBT [20,21]. Substantial improve-
ments in FOBT completion rates have been demon-
strated by studies that emphasized the importance of the
FOBT, increased patient confidence in their ability to
complete the FOBT, taught patients how to do the test,
and provided time for patients to ask and receive
answers to their individual questions about CRC and the
FOBT [20]. Intervention strategies resulting in higher
completion rates commonly involve one-on-one patient
contact in clinics by registered nurses which is costly,
time consuming [20], and uncommon in most commu-
nity-based fee-for-service clinical practices in Manitoba.
It may be more cost-effective to utilize a less expensive
strategy, specifically a telephone support line managed
by registered nurses. Another alternative may also in-
volve access to a website with CRC information and
FOBT assistance for patients. Although personalized
emails from a physician reminding patients to undergo
CRC screening and provided a link to a webpage with
information about CRC did not improve FOBT compli-
ance among patients [22], a multimedia educational
computer program was demonstrated to be as effective
as usual nurse counseling in educating patients and
achieving adherence to FOBT screening [23].
Both patients and family physicians seem to be
involved in a complex scenario resulting in sub-optimal
colorectal cancer screening rates. There has been pro-
gress in patient awareness of colorectal cancer and theimportance of screening [2]. A number of unique bar-
riers to FOBT screening remain which lead to poor pa-
tient compliance [3]. In 2008, a colorectal cancer
screening survey of 2,230 Manitobans aged 50 to 74 years
demonstrated that only 26% had an FOBT within the
previous year [3]. Factors identified by patients in the
survey as contributing to low uptake among those eli-
gible for CRC screening included: i) lack of knowledge
about CRC and understanding of the significance and
role of CRC screening in preventing and detecting the
disease [2]; ii) lack of familiarity with the purpose of the
FOBT; (iii) barriers associated with the test itself includ-
ing the instructions for performing the FOBT [24,25]
and iv) perception that the required collection of stool
samples is an unpleasant task [26]. Additional reasons
given by patients for not completing the FOBT included
that: i) they didn’t think it was really needed or neces-
sary (19%); ii) they thought the test sounded complicated
(3%); iii) they didn’t really understand the test and why
they should do it; iv) they did not want to handle stool
(3%); and v) they meant to but didn’t think about it or
forgot (3%) [3]. The survey also revealed that of those
provided with an FOBT, 10% did not complete it.
Among the reasons for completing an FOBT test, 79%
of Manitobans surveyed said that it was included as part
of a routine physical check-up or screening. Among
those who did not do the test, 75% said it was because
their doctor did not suggest it. This highlights the im-
petus and objectives of the protocol, to address the con-
straints of clinical practice and support family physicians
in initiating CRC screening with their patients while at
the same time, promoting patient understanding of the
disease and the desire to take action and complete the
test.
This protocol addresses the importance of promoting
understanding of the FOBT among patients as well as
their level of awareness, knowledge and education about
CRC and screening practices. At the same time, it
addresses the time constrains encountered by family
physicians in adequately addressing CRC screening with
their patients.
The patient decision aid used in this protocol is based
on the Health Belief Model in that patient health pre-
vention behaviors are largely determined by perceived
susceptibility and seriousness of a health threat or per-
sonal risk [21], the patients’ consideration of benefits
and barriers to action, including adequacy of informa-
tion to cue action and self-efficacy or confidence in the
ability to successfully take action [21]. Patient barriers to
FOBT compliance are consistent with the Health Belief
Model as they include limited accurate knowledge and
understanding of CRC and screening tests for CRC, low
perception of personal risk for CRC in the average-risk
population, inconvenience, aversion to stool testing, lack
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tion that the FOBT is time consuming, and fear of the
consequences of screening [18,20].
In 2009, 66% of Canadians 45 years and older went
online and represent an age group that is typically
slower to adapt to and use the internet [27]. In 2010,
77.1% of Canadians had home internet access compared
to 73% of Manitobans. Among those using the internet
from home, approximately 75% went online every day in
a typical month and 70% searched for medical or health
related information online [28]. Seventy-four percent of
females searched for information about health or med-
ical conditions compared to 66.7 of men. In 2009, 71.6%
of at home internet users were between 35–54 years of
age compared to 69.1% of those 55–64 years, and 65.9%
of those 65 years and older [29]. In 2010, 80% of indivi-
duals between the ages 45–64 used the internet com-
pared to approximately 51% aged 65–74 and 27% aged
75 years and older. Household income quartile as well as
urban versus rural community internet access are factors
influencing internet use [27]. The role of the internet in
assisting with and supporting positive health promotionFigure 1 The 12 community areas of Winnipeg, Manitoba, Canada. Th
St. James-Assiniboia, Assiniboine South, Downtown, River Heights, St. Bonif
involved in the province’s colorectal cancer screening program.behaviors in Manitoban’s age 50–74 years of age is cur-
rently unknown. Findings from the study outlined by
this protocol will illuminate whether the internet is a
possible medium for consideration as a means to sup-
port community-based family physicians in improving
colorectal cancer screening of their patients.
Methods/design
Setting and participants
Family physicians will be recruited over a six month period
from seven community areas (Figure 1) within the city
of Winnipeg, Manitoba, Canada. Winnipeg is the capital
city of the province with a population of approximately
685,000 (half the population of the province). In order to
be eligible for the study, FPs must be in regular family
practice (full or part-time), fee-for-service, solo or group
practice and may be a member of the Physician Integrated
Network and/or Uniting Primary Care and Oncology
Network (Table 1). Once a family physician/medical clinic
has agreed to participate in the study, a Family Physician/
Clinic Characterization Form (Additional file 2) will be
completed to document the routine care provided by eache seven community areas represented in the study protocol include
ace, St. Vital, and Fort Garry. These represent those areas not yet
Table 1 Description of stratification criteria Used in randomizing medical clusters to study groups
Stratification criteria Description
Physician Integrated Network (PIN) [30] A Manitoba Health primary care renewal initiative that focuses on
fee-for-service (FFS) physician groups.
Its goal is to facilitate systemic improvements in the delivery of primary care.
Objectives:
● To improve access to primary care
● To improve Primary Care Providers’ access to and use of information
● To improve the work life for all primary care providers
● To demonstrate high quality primary care with a specific focus on Chronic
Disease Management
Uniting Primary Care and Oncology
Network (UPCON) [31]
A collaborative partnership between Winnipeg family practice clinics/primary
health care centres and CancerCare Manitoba (CCMB) that is dedicated to
promoting and supporting the shared care of the cancer patient.
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with the FOBT, whether they utilized an electronic medical
record, have an on-site laboratory, and to document any
additional information necessary to ensure minimal intru-
siveness of the study protocol in the daily functioning of
the clinical practice. Each family physician will enroll 30–
35 patients who are: (1) attending their periodic health
exam; (2) considered at average risk of developing colorec-
tal cancer (Table 2); and (3) provide informed consent to
participate. A patient tracking form (Additional file 3) will
be filled out by the family physician for each patient
enrolled.
From our initial recruitment efforts, we determined
that there were three methods by which patients receive
an FOBT. Most FPs provide a laboratory requisition
form to patients who are then given the test kit by la-
boratory staff. Alternatively, the FPs support staff may
provide the FOBT kit directly to patients (with a requisi-
tion attached) or the FP may give the FOBT Kit directly
to their patients (with a requisition attached). All FPs
will continue with their current practice which will beTable 2 Patient eligibility criteria
Inclusion criteria Exclusion criteria
Attending for a Periodic
Health Examination
Walk-in patients
Males and females 50 to
74 years of age
Having had a colonoscopy
in the last 10 years
No symptoms of colorectal cancer Having had a flexible
sigmoidoscopy
within the last 5 years
No personal history of CRC, polyps,
or diseases of the colon requiring
monitoring by colonoscopy (Crohn’s
Disease or Ulcerative Colitis)
Having a double contrast
barium enema within the
last 5 years
Have a first degree relative with CRC
affected at age greater than 60
Have two or more second degree
relatives with polyps or cancerdocumented. Whether kit distribution method affects
patient FOBT uptake will be assessed. The rationale for
customizing this portion of the study protocol is to
optimize FP collaboration (recruitment) and to simulate
“real world” clinical practice. Hence, the study findings
will be relevant to practitioners and more likely used to
make evidence-based decisions that are translated into
practice.Sample size determination, randomization, and statistical
analysis
Individual randomization of physicians within a group-
practice and individual patients to either the control or
intervention arm of the study is not feasible [32]. A cluster
randomized design was chosen in which family physicians
within a group practice were randomized to the same
experimental group (control or intervention) and consid-
ered a cluster. Randomization of clusters will be conducted
by a biostatistician using a computer-generated list and all
of a physician’s patients will receive the same experimental
treatment (control or intervention). Our protocol defines a
multi-level analysis facilitating analysis of the intraclass cor-
relation coefficient (ICC) for each primary group-level out-
come (patients, FP, clinics/clusters) [32]. To ensure an
even distribution of cluster-level characteristics between
experimental groups, clusters will be randomized within
strata based on membership in the Physician Integrated
Network (PIN) and/or Uniting Primary Care Oncology
Network (UPCON) [28]. These represent two quality im-
provement initiatives in Manitoba (Table 2). Clusters will
be block randomized based on the number of collaborating
FPs within a practice. An absolute increase in FOBT
screening rates of 15% from the current 42% in Manitoba
will be considered clinically significant [14]. Sample size
was determined by a biostatistician using PASS (Power and
Sample Size, 2002) software and a computer simulated
ICC value of 0.6 [33] taking into consideration the
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estimate of the minimum detectable effect size (MDEF)
given the proposed sample size. Based on logistic regres-
sion a cluster size of 41 clusters each enrolling 30 to 35
patients (of which 80% are in the group that does not
utilize the supplied intervention/magnet and 20% are in
the group that does utilize the intervention/magnet; 1230
observations) will achieve 90% power at a 0.05 significance
level to detect a change from the baseline value of 0.400 to
0.550 and corresponds to an odds ratio of 1.833. In the
event that family physician collaboration/retention and/or
patient recruitment proves to be more difficult than antici-
pated, a logistic regression with a cluster size of 28 (840
observations) achieves 80% power with the same
outcomes.
Research has shown a majority of patients completing
the FOBT do so within 4 to 6 weeks [20]. In order to
allow adequate time to complete the FOBT and return it
to the laboratory, patients will be given four months to
do so. Those patients not returning their FOBT test
within a period of four months will be scored as failing
to complete the FOBT test.
Analysis of results will be based on the intention to
treat (ITT) model. All Statistical analysis will be per-
formed using SAS 9.2 W software. Categorical variables
will be compared using the Chi-square test. The time
taken to return FOBT cards will be analyzed with Cox’
Proportional Hazards Regression analysis. Due to the
clustered design, study outcomes will be measured at
the level of the patient, family physician, and medical
clinic/cluster. The analysis will utilize multi-level logistic
regression that accounts for variance among patients
with the same FP, FP within the same cluster, and among
the clusters. The SASW GLIMMIX procedure will be
used to model patient FOBT completion rate (response
variable). This will enable evaluation of the rate of pa-
tient FOBT compliance within medical clusters and indi-
vidual FPs. Sources of variance included in the model
will include cluster level (treatment, electronic medical
record or paper charts, PIN and/or UPCON member-
ship), family physician level (gender, solo/group prac-
tice), and patient level (age, gender, socioeconomic
status, and previous FOBT screening history) variables
as well as random variation.
A computerized randomization number list will be
used to select 10 patients per FP to be contacted for a
Post-Study Follow-Up Survey (Additional files 4 and 5)
conducted by telephone. Only those patients providing
permission to be contacted will be included. Those
patients surveyed will be asked for permission to docu-
ment their Personal Health Identification Number which
will facilitate future studies conditional to Health Re-
search Ethics Board (HREB) approval of analysis of re-
peat colorectal cancer screening behavior over time.Creating collaborative partnerships between community-
based family physicians and primary healthcare
researchers
The first step in creating the collaborative partnerships
with Winnipeg family physicians will involve composing
a list of medical clinics and community-based family
physicians within the outlined community areas. Once
defined, the study coordinator (KC) will make rando-
mized cold-calls to each medical clinic to inform them
of the study and delivery of the primary care provider
(PCP) recruitment letter. The PCP recruitment letter
briefly outlines the proposed research study, provides in-
formation on a small honorarium to acknowledge the
efforts of the FP/clinics ($500.00 for 1 to 2 FPs; $1000.00
for 3 to 5 FPs; $1,500.00 for 6–9 FPs; and $2,000.00 for
≥10 FPs) and inquires about interest in collaborating on
the study. Meetings will be arranged with interested
FPs/clinics to outline the study in more detail and to de-
termine collaboration. All methods used establish collab-
orative partnerships with FPs will be documented in an
attempt to establish insights into those strategies that
best support these efforts.
Experimental treatment group
All FPs will follow their usual clinical practice for CRC
screening with the FOBT during the patient periodic
health examination. FPs in the intervention group will
provide patients with access to the study specific colo-
rectal cancer information and screening nurse-managed
telephone support line and website by giving them a re-
frigerator magnet with the telephone number and web-
site URL (Figure 2). Access to the telephone support line
and/or website is patient initiated. All patients in both
treatment groups will be assigned a study-specific, seven
character, alpha-numeric identification number. For
patients allocated to the intervention group, each
patient’s magnet will be assigned the same study-specific
identification number which will be used by patients in
the experimental group to access the telephone and
website patient aids, facilitate tracking patient use of the
intervention support tools, and protect personal health
information.
The colorectal cancer information and screening
telephone support line and website
The scientific literature and credible health resources
[1,3,8,9,11-13] will be used to gather patient relevant
colorectal cancer and screening information. Patient
health education files will be generated based on this in-
formation to address patient’s most common questions
and issues related to FOBT screening [3,8-10]. A survey
conducted in Manitoba [3] and personal communica-
tions between the study coordinator (KC), family physi-
cians and their support staff, and lab technicians will
Figure 2 Study magnet design. Family physicians randomized to
the intervention treatment group will provide each of their patients
with a study refrigerator magnet (shown above) containing a unique
seven character alpha-numeric study identification number that (1)
facilitates access to the patient decision aids (a nurse-managed
telephone support line and a website), (2) is linked to the Patient
Tracking Form used by the family physician during the periodic
health examination, and (3) linked to In-Clinic Patient Survey
(Additional file 6). Family physicians will enroll between 30 to 35
patients who have provided their consent to participate in the
study. The magnet was designed by the CIHR/CCMB Primary Care
Oncology Research Team.
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Website resource development was based on the same
information in addition to feedback from CRC patients/
survivors (n = 4), two small groups (n = 5–8) of average
risk men and women, and the PCO-NET group during
three quarterly workshops.
Each patient will provide the registered nurse taking
the call with their personal seven digit alphanumeric
study identification number. Similarly, patients logging
on to the website will be guided to enter their study
identification number and create a personal password
that allows them access to the site. Patients initiating aFigure 3 Site Map for the colorectal cancer information and screening
password to access to the study website, please contact Dr. Kathleen Clouscall to the telephone line will be able to ask questions
which will be answered by a registered nurse using the
health education files. If a patient asks a question to
which there is no health education file/answer, the ques-
tion will be documented by the registered nurse and the
patient given the contact information of the study co-
ordinator and/or provided the website address. Patients
logging on to the website are able to view each webpage
according to their specific questions and areas of interest
(Figure 3 for website site map). Each page visited by
each patient will be recorded. Patients will be able to
email the study coordinator if they have further ques-
tions/comments. We will be able to track the number of
calls made by each patient, the health education files
accessed by each patient, the number of times they ac-
cess the website and the website content/pages they visit,
as well as any additional questions asked that were not
contained in the health education files or website. Pa-
tient study identification number will correspond to the
study identification number on the Patient Tracking
Form which facilitates linking patient demographic in-
formation, FOBT completion status, and In-Clinic and
Follow-Up Survey data with telephone and website
usage.
Description of the study protocol
This study protocol was approved by The University of
Manitoba Health Research Ethics Board (Additional files
7, 8, 9 and 10) and is outlined in detail in Figures 4, 5, 6
and Tables 3–4. Table 5 provides an outline of and link
to the study protocol forms and surveys along with a
summary of the information obtained from each and
the anticipated number of responses. Table 6 provides a
description of the contents of the study set-up package.
Upon arrival for their periodic health examination, eli-
gible patients (Table 2) in both study groups will bestudy website. To obtain a website identification number and
ton (kclousto@cc.umanitoba.ca).
Figure 4 Flow Diagram of study protocol for family physicians. Ψ, strata based on membership in the Physician Integrated Network (PIN)
and/or Uniting Primary Care and Oncology Network (UPCON); blocked based on the number of family physicians per cluster.
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In-Clinic Patient Survey. This survey provides an ex-
planation of the study and asks the patient to respond
to a few general questions related to colorectal cancer
screening, computer use for health-related questions,
and permission to be contacted for the follow-up sur-
vey. It will function as the patient consent form. A
business card will be attached to each In-Clinic Patient
Survey providing the telephone numbers for the Uni-
versity of Manitoba Health Research Ethics Board and
the Study Coordinator to facilitate patient contact as
necessary. Patients declining to answer the survey re-
turn it to the clinic support staff who document that
the patient declined to participate. Those patients com-
pleting the In-Clinic Survey will bring it with them and
gave it to their FP during their periodic health examin-
ation. The FP will determined patient eligibility. All FPsconduct CRC screening as per their standard clinical
practice. If a patient is ineligible, the FP will not enroll
the patient. If the patient is eligible, the FP will enroll
the patient by filling out a Patient Tracking Form. FPs
will have a Patient Tracking Form Binder containing a
Patient Tracking Form for each eligible patient in each
of their evaluation rooms. Each Patient Tracking Form
will have a removable sticker with the unique study
identification number on it. The FP will remove and
affixed this sticker to the patient’s In-Clinic Survey.
Patients will be given four months to complete their
FOBT. FPs in the intervention group will provide each
eligible patient with a refrigerator magnet (paper
clipped to the corresponding Patient Tracking Form).
The protocol design allows us to determine how many
patients provided with the magnet called the telephone
support line as well as the number of times they called
Figure 5 Flow diagram of control group Study Protocol for family physicians and support staff. * Family Physicians will complete the
Family Physician Survey (Additional file 11) upon completion of study requirements. Please refer to text for further details.
Clouston et al. BMC Cancer 2012, 12:182 Page 9 of 15
http://www.biomedcentral.com/1471-2407/12/182and their most common questions. It also allows us to
determine which patients accessed the website, the
pages they visited, and the information they were most
interested in. Approximately four months after the last
patient is enrolled, each FP will be provided with a list
of their enrolled patients on which they will document
the date of FOBT completion for those patients com-
pleting the test or an incomplete (for those not com-
pleting the FOBT). Patient FOBT results will not be
collected. Using a computer generated randomization
list, 10 patients per FP who agreed to be contacted for
the Post-Study Follow-Up Survey will be contacted via
telephone to complete the survey.
The study coordinator will conduct site visits at regu-
lar intervals (approximately every two to three weeks) to
facilitate regular communication, answer questions, and
address issues with family physicians/support staff/med-
ical clinics, build rapport and trust with partners, ensuresuccessful study protocol implementation, and to pick
up In-Clinic Surveys and Patient Tracking Forms.
Primary outcome
The primary outcome of the study is the proportion of
patients in each group who complete the FOBT test and
returned it within four months. The proportion of
patients in the intervention group who access the tele-
phone support line and/or website will be determined.
Of those who access the patient aids, the number of
patients who complete their FOBT will be determined to
facilitate evaluation of whether access to the patient aids
by intervention group patients increased their rate of
FOBT completion compared to the control group
patients. Our findings will assist in determining whether
the patient aids offered to the intervention group may
be a useful tool to support FP in their CRC screening
efforts and improve patient uptake of the test.
Figure 6 Flow diagram of intervention group study protocol for family physicians and support staff. * Family Physicians will complete the
Family Physician Survey upon completion of study requirements. Please refer to text for further details.
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Secondary outcomes of the study include determining
the most common questions of average-risk Manitoban
patients’ related to CRC and FOBT screening and evalu-
ating their experience with the telephone support line
and/or website including helpfulness, number of times
accessed, and preference for the telephone support line
and/or website. Factors related to patient noncompliance
will also be evaluated in post-study Follow-Up Survey.
Each FP collaborating on the study was asked to
complete a Family Physician Survey developed specific-
ally for the study and will provide feedback from family
physicians related to FOBT screening, their experience
participating in this practice-based primary care researchstudy, and the implementation/utilization of the patient
aids in their clinical practice. All FPs will be provided
with the study findings. In particular, FPs will be pro-
vided with their patient FOBT completion rates as well
as those of their colleagues and the clinics collaborating
in the study. All findings are confidential and reported
anonymously. Costs of implementation of both the tele-
phone support line and website will be evaluated.
Discussion
Family physicians understand that colorectal cancer
screening using the FOBT is effective in reducing colo-
rectal cancer mortality and their patients are becoming
more aware of the importance of screening. However,
Table 3 Study protocol steps for control group
Study protocol
step
Description/details of study protocol step
STEP #1 Patients between the ages 50–74 report to the
reception desk/support staff for their Periodic
Health Examination (PHE) or regular visit in which
the family physician determines there is an
opportunity for colorectal cancer screening
(Fecal Occult Blood Test; FOBT).
STEP #2 Support staff provide patients meeting the above
criteria with the In-Clinic Patient Survey (found
in the study binder marked In-Clinic Patient
Surveys) on a clipboard.
STEP #3 Patient decides whether they will fill out the
In-Clinic Survey.
If a patient declines to fill out the In-Clinic Survey,
the support staff documents the patient’s age,
gender, and reason(s) they declined to fill out
survey (on the back of the In-Clinic Survey). Please
clip the survey to the front of the study binder
marked In-Clinic Patient Surveys.
If a patient fills out the survey, they take it with
them and give it to their family physician at the
beginning of their appointment. The clipboard is
returned to support staff so they are able to use it
for the next patient.
STEP #4 The patient gives their In-Clinic Patient Survey to
their family physician at the beginning of their
appointment.
STEP #5 The family physician takes the In-Clinic Survey
from the patient and determines if they are
eligible for the study based on the inclusion/
exclusion criteria found at the front of the family
physicians study binder marked Patient
Tracking Forms.
If patients are ineligible, clip the In-Clinic Survey
to the front of study binder marked Patient
Tracking Forms.
If patients are eligible:
Turn to an unused Patient Tracking Form in the
study binder. Record the date, the patient’s NAME,
and mark the checkbox indicating the method of
FOBT distribution to the patient.
Remove the study ID number sticker from the
Patient Tracking Form and place it on the patient’s
In-Clinic Survey.
Clip the In-Clinic Survey to the front of the
Study Binder.
Proceed with colorectal cancer screening with
the Fecal Occult Blood Test (FOBT) as per usual
clinical practice.
STEP#6 Study coordinator (Dr. Kathleen Clouston) will
arrange a convenient date to collect forms and
determine those completing their FOBT. In the
event that you require more In-Clinic Surveys or
have a question/comment/concern, please
contact Dr. Clouston at 272–3086 or
kclousto@cc.umanitoba.ca
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complex set of barriers exists for both family physicians
and their patients.If our findings demonstrate that utilization of the tele-
phone support line and/or website result in clinically sig-
nificant increases in FOBT compliance by average-risk
Manitobans, changes in CRC screening at the policy-
and system-level may be warranted. A strong and trust-
ing family physician-patient relationship, combined with
the patient intervention (education and decision aid)
and public health programs to increase awareness of
CRC and screening (ColonCheck Manitoba) has the po-
tential to increase FOBT CRC screening rates, decrease
CRC mortality and morbidity and improve the health of
Manitobans.
It is expected that the patient-centered strategies out-
lined in the above protocol will support family physi-
cians in improving patient understanding of CRC, the
importance of FOBT screening in average-risk indivi-
duals as well as providing specific instructions on how
to conduct the FOBT. Hence, it has the potential to
lead to improved rates of patient FOBT compliance.
Clinic, physician, and patient level variables associated
with FOBT completion will be assessed for potential
usefulness in planning strategies to target specific high-
risk patient populations that require additional focus
and supportive strategies for family physicians in
Manitoba.
It is unknown what level of comfort/ease/accept-
ance Manitoban patients in the appropriate age range
for CRC screening have with accessing/utilizing web-
based health information and whether it has potential
to be an effective venue through which FP could
provide preventive health information to patients.
This study will attempt to shed some light in this
area.
Even if the outcome of the outlined study is negative,
the findings will provide useful information regarding
the limitations of the guaic based FOBT test in CRC
screening and barriers to patient completion of the test.
New potential research directions and study questions
may also be generated.
Family physicians interested in collaborating in re-
search face challenges including time pressures, minimal
infrastructure to support the additional requirements of
research, and lack of access to information about on-
going research projects. In addition, their role primary
healthcare research is often undervalued. We will docu-
ment the factors involved in establishing the collabora-
tive partnerships with the community-based family
physicians in the outlined protocol.
This will allow us to contribute to the limited existing
knowledge regarding successful partnerships among pri-
mary healthcare researchers and community-based fam-
ily physicians as well as the unique requirements to
support integrated knowledge translation and evidence-
based decision making.
Table 4 Study protocol steps for intervention group
Study protocol step Description/details of study protocol step
STEP #1 Patients between the ages 50–74 report to the reception desk/support staff for their Periodic Health Examination
(PHE) or regular visit in which the family physician determines there is an opportunity for colorectal cancer
screening (Fecal Occult Blood Test; FOBT).
STEP #2 Support staff provides patients meeting the above criteria with the In-Clinic Patient Survey (found in the
study binder marked In-Clinic Patient Surveys) on a clipboard.
STEP #3 Patient decides whether they will fill out the In-Clinic Survey.
If a patient declines to fill out the In-Clinic Survey, the support staff documents the patient’s age, gender,
and reason(s) they declined to fill out survey (on the back of the In-Clinic Survey). Please clip the survey to
the front of the study binder marked In-Clinic Patient Surveys.
If a patient fills out the survey, they take it with them and give it to their family physician at the beginning
of their appointment. Clipboard is returned to support staff so they are able to use it for the next patient.
STEP #4 The patient gives their In-Clinic Patient Survey to their family physician at the beginning of their appointment.
STEP #5 The family physician takes the In-Clinic Survey from the patient and determines if they are eligible for the study
based on the inclusion/exclusion criteria found at the front of the family physicians study binder
marked Patient Tracking Forms.
If patients are ineligible, clip the survey to the front of Study Binder
If patients are eligible:
Turn to an unused Patient Tracking Form in the Study Binder and record the date, the patient’s NAME, and
mark the checkbox indicating the method of FOBT distribution to the patient.
Remove the study ID number sticker from the Patient Tracking Form and place it on the In-Clinic Survey.Remove
study magnet from Patient Tracking Form and give it to the patient. Clip the In-Clinic Survey to the front of
the Study Binder.
Proceed with colorectal cancer screening with the Fecal Occult Blood Test (FOBT) as per usual clinical practice.
STEP#6 Study coordinator (Dr. Kathleen Clouston) will arrange a convenient date to collect forms and determine those
completing their FOBT. In the event that you require more In-Clinic Surveys or have a question/comment/concern,
please contact Dr. Clouston at 272–3086 or kclousto@cc.umanitoba.ca
Table 5 Outline of study protocol forms and surveys and anticipated number of responses
Study protocol form/survey Individual completing
form/survey
Information obtained Anticipated number
of responses
Clinic Characterization Form1 Medical Cluster and
Family Physician
Standard FOBT practice; Electronic medical record;
on-site lab; solo/group practice
50 to 80
Family Physician Survey2 Family Physician Experience with study protocol and value to
clinical practice; facilitators and barriers to study
collaboration; interest in future community-based
primary healthcare research projects
50 to 80
FOBT Completion Status Form Family Physician Patient FOBT status four months post requisition) 50 to 80
Patient Tracking Form3 Family Physician Date of FOBT requisition; Patient name; FOBT kit
distribution method
1,500 to 2,400
In-Clinic Patient Survey4 Patient Age, gender, postal code, Previous FOBT screening
history, internet use for health related questions;
exposure to advertisements related to FOBT
screening; consent for Post-Study Follow-Up Survey
1,500 to 2,400
Post Study Follow-Up Survey
(control)5
Patient (10 patients per
family physician)
Colorectal cancer screening and FOBT experience
with family physician; FOBT test instructions;
computer access frequency of use; facilitators and
barriers to completing the FOBT; Personal Health
Information Number
250 to 400
Post Study Follow-Up Survey
(intervention)6
Patient (10 patients per
family physician)
Colorectal cancer screening and FOBT experience
with family physician; FOBT test instructions;
computer access frequency of use; facilitators
and barriers to completing the FOBT; experience
with and usefulness of patient decision aids
(telephone-support line and website); Personal
Health Information Number
250 to 400
1, 2, 3, 4, 5, 6 Additional files 2, 11, 3, 6, 4 and 5 for each form and survey.
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Table 6 Description of study set-up package
Study package delivered to each collaborating family physician Description/details
In-Clinic Patient Survey Binder(s): Contents:
● thank you page for support staff ● In-Clinic Patient Surveys for support staff
● step-by-step outline of the study protocol, ● business card attached to each survey providing contact information
for the study coordinator and the University of Manitoba Health Research
Ethics Board (attached to clipboards and replaced when necessary)
● step-by-step flow diagram of the study protocol
● patient eligibility criteria
● contact information for the study coordinator
Clipboards with pens Two clipboards and pens per family physician
Patient Tracking Form Binders: ● Each family physician is provided with one Patient Tracking Form Binder
per evaluation room (usually two)
● step-by-step outline of the study protocol ● the 30–35 Patient Tracking Forms are split between the these binders
● step-by-step flow diagram of the study protocol
● patient eligibility criteria ● Each Patient Tracking Form corresponds to a specific patient with
corresponding seven-digit alphanumeric study identification number
● contact information for the study coordinator ● family physician records the date of FOBT requisition, patient’s name, FOBT
distribution method, removes the sticker from the form and attaches it to the
corresponding patient’s In-Clinic Survey
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There are a few limitations of this study protocol which
are outlined as follows:
(1)Inclusion of the In-Clinic Patient Survey in both
treatment groups may raise patient awareness about
CRC and screening sufficiently to affect/improve
screening rates even without the intervention
(magnet). To address this we will look at the CRC
screening rates in the control group and compare
them to historical rates.
(2)Those family physicians agreeing to participate in the
study may have done so with awareness that their
patients (screening process) have a relatively higher
screening rate and degree of success with screening.
FP declining to participate may have lower patient
CRC screening rates and be concerned about
participating, the perception of being evaluated, and
how it reflects on their practice. It may be that these
FP-patient populations have the most to gain/highest
potential to benefit from the intervention. It may be
that, in certain populations, the intervention increases
screening rates more than in others.
(3)Some providers (PIN and UPCON) are involved in
other quality improvement interventions. Therefore,
these clinics may have a specific approach to
screening that has already lead to improvements in
patient CRC screening rates and functioning/
practice may be more evidence-based compared to
those that are not involved in these initiatives. In
these groups, the study intervention may have
minimal effect.
(4)Only fee-for service FPs are included. Therefore, the
results may be applicable only to this type of provider.(5)FP and patients represent an urban geographical
area and therefore, results may not be generalizable
to patient populations in rural areas.
(6)Disparity in accessing the website patient aid is a
likely factor for individuals living in rural
communities and those with a lower socioeconomic
status. Those patients agreeing to the follow-up
survey may be more apt to complete the FOBT.
Therefore, feedback from those prone to fail to
complete the test may be under represented.
Benefits
There are a number of benefits of the study protocol
which are outlined as follows:
(1)The pragmatic design and flexibility of the protocol
for each medical practice ensured it reflected the
“real world” clinical practice environment and its
inherent variability. This approach will produce
findings that are generalizable and relevant to
community-based family practice and will increase
translation and application of evidence-based
findings into the clinical practice setting. The study
was powered to detect an absolute increase in CRC
screening rates of 15% by the intervention. This is a
realistic and clinically significant improvement.
(2)The multi-disciplinary team working together on
this project represent multiple stakeholder opinions
and contributions (primary care providers, primary
care researchers, policy makers, and patients). It also
reflects a variety of providers/practitioners all of
which enhance the pragmatic nature of the design
and findings. Working collaboratively on this
research project facilitated creation of new
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the potential to support future primary healthcare
research that inform evidence-based family practice.
(3)Findings will allow us to describe the degree of
variability in screening rates among the medical
clinics and practitioners involved in the study and,
the rates of internet usage among the age category
50–74 for a health-related issue, and more
specifically, CRC information and screening.
(4)Findings will provide valuable patient feedback about
the FOBT and the common issues related to
completion/non-compliance with the test.
(5)The study is highly representative of the
community-based clinical practice environment and
included a variety of FPs from a number of different
areas in the city and practice settings.
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